Vertex Pharmaceuticals company info

What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals (NASDAQ:VRTX) focuses on developing and commercializing innovative therapies for treating cystic fibrosis (CF) and other severe diseases. The company is recognized for its leading portfolio of CF treatments which significantly improve the lives of those affected by this genetic disorder. Beyond CF, Vertex is expanding its research and development efforts into other serious diseases, aiming to apply its scientific expertise in creating transformative medicines. The overarching objective of Vertex is to deliver groundbreaking treatments that can profoundly impact the quality of life for patients with severe and life-threatening diseases. NASDAQ:VRTX is the sole exchange where Vertex Pharmaceuticals is traded, making it a noteworthy entity in the biotechnology sector for investors and industry stakeholders alike.
Vertex Pharmaceuticals company media
Company Snapshot

Is Vertex Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Vertex Pharmaceuticals employ?

people
Employees
5,380

What sector is Vertex Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Vertex Pharmaceuticals?

location pin
Head Office
Boston, United States

What year was Vertex Pharmaceuticals founded?

founded flag
Year Founded
1989
What does Vertex Pharmaceuticals specialise in?
/Cystic Fibrosis /Medicinal Research /Drug Development /Innovative Therapies /Genetic Diseases /Healthcare Solutions

What are the products and/or services of Vertex Pharmaceuticals?

Overview of Vertex Pharmaceuticals offerings
Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) - a leading medication for the treatment of cystic fibrosis, targeting the F508del mutation in people aged 6 years and older.
Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor) - a treatment for cystic fibrosis in patients aged 6 years and older with specific mutations in the CFTR gene.
Orkambi (lumacaftor/ivacaftor) - designed for the treatment of cystic fibrosis in patients age 2 and older who have two copies of the F508del mutation in their CFTR gene.
Kalydeco (ivacaftor) - a medication for the treatment of cystic fibrosis in patients aged 6 months and older with one of 38 ivacaftor-responsive mutations in the CFTR gene.
Type 1 Diabetes therapy through the acquisition of ViaCyte, Inc. - focused on stem cell therapy that has the potential to provide a functional cure for type 1 diabetes.
CRISPR/Cas9 gene-editing therapy in collaboration with CRISPR Therapeutics for the treatment of sickle cell disease and beta thalassemia, aimed at correcting mutations in the HBB gene coding for the beta-globin chain.

Who is in the executive team of Vertex Pharmaceuticals?

Vertex Pharmaceuticals leadership team
  • Dr. Jeffrey Marc Leiden M.D., Ph.D.
    Dr. Jeffrey Marc Leiden M.D., Ph.D.
    Executive Chairman
  • Dr. Reshma  Kewalramani FASN, M.D.
    Dr. Reshma Kewalramani FASN, M.D.
    CEO, President & Director
  • Mr. Charles F. Wagner Jr.
    Mr. Charles F. Wagner Jr.
    Executive VP & CFO
  • Mr. Stuart A. Arbuckle B.Sc.
    Mr. Stuart A. Arbuckle B.Sc.
    Executive VP & COO
  • Dr. David M. Altshuler M.D., Ph.D.
    Dr. David M. Altshuler M.D., Ph.D.
    Executive VP & Chief Scientific Officer
  • Ms. Kristen C. Ambrose CPA
    Ms. Kristen C. Ambrose CPA
    Senior VP & Chief Accounting Officer
  • Mr. Mike  Tirozzi
    Mr. Mike Tirozzi
    SVP and Chief Information & Data Officer
  • Susie  Lisa
    Susie Lisa
    Senior Vice President of Investor Relations